AI Drug Discovery: Demis Hassabis and Isomorphic Labs Aim to Tackle Chemical Complexity

On October 23, 2026, Fortune magazine published an article highlighting the work of Demis Hassabis, co-founder of Google DeepMind and Nobel Laureate, and his venture, Isomorphic Labs. Established in 2021, Isomorphic aims to harness AI to navigate the vast chemical space—estimated at 10^60 small, drug-like molecules—potentially revolutionizing drug discovery. Hassabis envisions a systematic approach to developing treatments using advanced AI platforms, moving beyond traditional serendipitous discoveries like penicillin. The company's mission is not merely to "cure" diseases but to create scalable processes for discovering, designing, and optimizing drugs as needed. Despite lacking clinical trials, Isomorphic emphasizes the importance of demonstrating tangible results through actual drug development. Investor Krishna Yeshwant underscores the necessity of proving efficacy by bringing drugs to market. As AI-driven drug discovery enters a new phase demanding concrete outcomes, Isomorphic's success could redefine treatment paradigms for conditions ranging from autoimmune disorders to cancer, promising a transformative impact on healthcare within the next decade.